Skip to main content
. Author manuscript; available in PMC: 2020 May 4.
Published in final edited form as: Biometrics. 2019 Sep 19;76(1):304–315. doi: 10.1111/biom.13116

Table 3.

Regime selection percentage based on the proposed two-stage design under the eight scenarios in Table 1. The accrual rate is 6 patients per month. These values for optimal treatment regimes with uc,r>ucmax5 are underlined, where ucmax=maxr{uc,r} is the maximum utility for subgroup c, c = 1, 2.

Scenario Schedule/dose Subgroup 1 Subgroup 2

1 2 3 1 2 3
1 1 0.0 0.3 38.7 0.1 0.7 33.6
2 49.4 6.7 0.8 51.4 6.1 0.9
3 4.0 0.1 0.0 7.1 0.1 0.0

2 1 31.7 11.8 0.3 30.0 13.1 0.2
2 3.8 0.8 0.6 4.8 1.4 0.2
3 9.1 37.5 4.4 8.3 37.1 4.9

3 1 1.0 17.3 0.0 3.5 16.6 0.0
2 56.3 0.7 0.0 49.4 1.4 0.0
3 3.1 4.2 17.4 5.2 5.0 18.9

4 1 0.1 6.3 60.9 0.9 5.8 56.7
2 5.8 13.1 3.2 3.9 21.7 3.9
3 2.7 7.4 0.5 1.8 5.1 0.2

5 1 1.1 8.7 3.1 1.2 5.4 3.2
2 0.6 57.9 1.6 1.1 50.3 1.8
3 15.0 11.1 0.9 11.0 24.6 1.4

6 1 0.9 5.2 3.2 0.8 30.6 17.4
2 2.4 37.1 3.5 1.1 22.6 2.7
3 42.7 5.0 0.0 22.7 2.1 0.0

7 1 1.1 45.4 4.2 1.0 35.4 2.7
2 11.2 37.1 0.6 28.9 31.3 0.3
3 0.4 0.0 0.0 0.4 0.0 0.0

8 1 2.4 7.2 47.2 1.9 5.3 42.3
2 2.7 0.2 0.0 2.6 0.3 0.0
3 21.5 11.7 7.1 13.9 10.4 23.3